EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation.

EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation.

Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, has achieved high clinical response rates in patients with non-small cell lung cancers (NSCLCs). However, over time, most tumors develop acquired resistance to EGFR-TKIs, which is...

Full description

Bibliographic Details
Main Authors: Teppei Yamada, Koichi Azuma, Emi Muta, Jintaek Kim, Shunichi Sugawara, Guang Lan Zhang, Satoko Matsueda, Yuri Kasama-Kawaguchi, Yuichi Yamashita, Takuto Yamashita, Kazuto Nishio, Kyogo Itoh, Tomoaki Hoshino, Tetsuro Sasada
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3818324?pdf=render

Internet

http://europepmc.org/articles/PMC3818324?pdf=render

Similar Items